|
PennyPerformers.com: "Penny Stocks that Perform" picks are: AWEC, BSRC, CBAI, NNVC, UNCO
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:09022009
Pennyperformers.com "Penny Stocks that Perform" picks are: Ameriwest
Energy Corp. (OTCBB: AWEC), BioSolar, Inc. (OTCBB: BSRC), Cord Blood
America, Inc. (OTCBB: CBAI), NanoViricides, Inc. (OTCBB: NNVC), Unico,
Incorporated (OTCBB: UNCO)...and Proudly Introducing Proprietary Push
Technology (PPT).
The Newest and Revolutionary Technology for Increasing Investor
Visability.
REAL Awareness for REAL Companies.
Click below for a full demonstration.
http://newmediaadvisors.info/newmedia.swf
Sign-up for our FREE Stock Alerts AND NEWSLETTER at
www.pennyperformers.com
Feb 09, 2009 -- Ameriwest Energy Corp. (OTCBB: AWEC) ("Ameriwest" or
the "Company") wishes to update the status as regards plans for the
upcoming spud of the Ameriwest Fee #1 well to be drilled at the
Company's Geary Prospect located in the Powder River Basin of Wyoming.
Ameriwest has submitted a $20,000 Certificate of Deposit as required by
the Wyoming Oil and Gas Conservation Commission and has further
submitted all required paperwork in order to receive the requisite
Permit to Drill at the Ameriwest Fee #1 well location. The company
expects to receive final approval and issuance of the permit within the
next 7 days. Following the issuance of the Permit, Ameriwest intends on
commencing site preparations as early as the third week in February in
order to spud the Ameriwest Fee #1 well as previously announced on or
near to March 16, 2009.
As noted in an earlier announcement, the proposed well is "on fee"
(located on private lands) which has significantly expedited the
permitting process. The Geary Prospect is located in a prolific portion
of the Powder River basin that has historically produced many millions
of barrels of oil from such well known nearby fields as Brooks Ranch,
Big Muddy, South Glenrock, and South Cole Creek to name but a few. The
target location is offset to 2 wells located in a well documented part
of the Geary Dome field with considerable cumulative production to-date.
The main objective is structurally on trend with existing production
within the Cretaceous Dakota sandstone formation with the possibility
of production from other Cretaceous sands including the Upper and Lower
Muddy, and Wall Creek (Frontier) sands. Initial estimates based on a
full field program with 40 acre spacing across an estimated 18 wells
indicate possible reserves of approximately 3 MMBO.
Company President Walter Merschat comments, "With this announcement, we
are confidently on track towards getting our equipment into the field
in short order. Site prep is the next step and with the delivery of the
updated data we aim to receive from our independent geologic analysis
due within a week, we look forward to getting out there and finalizing
matters. Every week is getting us that much closer to watching the
drill turn."
About Ameriwest Energy Corp.
Ameriwest Energy Corp. is a growing, expertly managed energy company
focused on producing underdeveloped oil resources in the prolific Rocky
Mountain region of the United States. The company is striking a
strategic balance between low-risk tertiary recovery projects and
extensively mapped exploration plays with significant upside potential.
Feb 09, 2009 -- BioSolar, Inc. (OTCBB: BSRC), developer of a
breakthrough technology to produce bio-based materials from renewable
plant sources that reduce the cost of photovoltaic solar modules,
reports that results of testing on BioBacksheet(TM) samples from the
first pre-production runs have been consistent and satisfactory; which
gets the company one step closer to full scale commercial production.
The BioBacksheet(TM), a protective covering for photovoltaic solar
cells made from renewable plant sources, rather than the expensive
petroleum-based film currently in use, is expected to cost less than
traditional petroleum-based backsheets. Backsheets are used in
virtually all solar panels.
"Aside from cost and environment-friendly advantages, BioBacksheets(TM)
can now be manufactured in various colors," said Dr. David Lee, CEO of
BioSolar. "This feature will further differentiate BioBacksheet(TM)
from existing petroleum-based backsheets since this is not even an
option for them. Photovoltaic module manufacturers often favor color
adaptation to maintain aesthetic consistency for their current solar
panel."
BioSolar has been in a pre-production stage for its BioBacksheet(TM)
for the last several months, and has conducted extensive quality
control tests on samples of each pre-production run.
"The test covers material properties, mechanical properties, electrical
properties, and appearances before and after the long term durability
tests which include a 1,000-hour damp heat oven test, simulating more
than 20 years of real world extreme conditions," said Lee.
BioSolar's backsheet technology was featured in a January edition of
the Technology and Business Journal, as well as Energy Weekly News.
About BioSolar, Inc.
BioSolar, Inc. has developed a breakthrough technology to produce
bio-based materials from renewable plant sources that will reduce the
cost per watt of solar cells. Most of the solar industry is focused on
photovoltaic efficiency to reduce cost. BioSolar is the first company
to introduce a new dimension of cost reduction by replacing
petroleum-based plastic solar cell components with durable bio-based
materials.
Feb 09, 2009 -- Cord Blood America, Inc. (OTCBB: CBAI), the umbilical
cord blood stem cell preservation company
(http://www.cordblood-america.com) focused on bringing the life saving
potential of stem cells to families nationwide and internationally,
said today that the Company is now listed on the ETF Innovators
Emerging Stem Cell Index of U.S.-listed stocks.
ETF Innovators, known for creating new global equity indexes with a
focus in the healthcare industry, will track the total market value and
stock price changes as an indicator of investor and trader sentiment
toward the stem cell and regenerative medicine space.
"We are pleased by this recognition. Two thousand and nine has been, so
far, both very interesting and positive for stem cell companies, and
we're pleased to see this impressive index following our sector," said
Matthew Schissler, Founder and CEO of Cord Blood America.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates
umbilical cord blood stem cell preservation for expectant parents and
their children. Its mission is to be the most respected stem cell
preservation company in the industry. Collected through a safe and
non-invasive process, cord blood stem cells offer a powerful and
potentially life-saving resource for treating a growing number of
ailments, including cancer, leukemia, blood, and immune disorders.
Feb 09, 2009 -- NanoViricides, Inc. (OTCBB: NNVC) (the "Company"),
reported today that on-going negotiations with a large pharmaceutical
company have now progressed to an advanced stage. The pharmaceutical
company initially plans to evaluate NanoViricides's drug candidate for
effectiveness against external ophthalmic diseases caused by two
different virus types, namely herpes simplex virus (HSV) and
adenovirus. These evaluations will be performed by an independent
research institute that specializes in diseases of the eye.
HSV and some adenoviruses cause most of the cases of keratitis, a
serious infection of the cornea. Importantly, HSV infection can lead to
corneal scarring that may necessitate corneal transplantation. In
addition, some adenoviruses cause a majority of conjunctivitis cases
("pink eye"). The remaining cases of conjunctivitis, caused by
bacteria, are treatable with topical antibiotics. Currently, there are
no effective treatments for viral diseases of the exterior portion of
the eye.
The Company has already demonstrated strong efficacy against an
adenovirus-caused external eye disease called epidemic
kerato-conjunctivitis (EKC). Rapid clinical improvement in the treated
animals was reported by independent researchers who tested the effects
of the nanoviricides drug candidate against adenoviral EKC. Based on
computer modeling, the Company believes that the broad-spectrum nature
of the ligand used in this nanoviricide should enable it to be
effective against HSV.
The total market for viral conjunctivitis is estimated to be in the
billions of dollars. The incidence of severe herpes keratitis is
estimated to be 250,000 cases per year in the USA. In Japan, where EKC
is a reportable disease, it is estimated that there are at least one
million cases per year. The number of cases of non-specific
conjunctivitis (pink eye) is considered to be far greater, possibly
into tens of millions in the US, and into hundreds of millions
worldwide.
The Company will need to procure large quantities of the nanoviricides
drug candidates for the upcoming studies. In order to support this
production scale, TheraCour Pharma, Inc., the Company's largest
shareholder and licensor of the technology that the Company uses in its
anti-viral drug development, has initiated a program to expand its
laboratory facilities. TheraCour has entered into a Rule 10b5-1 trading
plan to sell, over a one year period, up to 1.8 million shares of the
Company's common stock that it owns. The proceeds are to be used to pay
for the necessary improvements in laboratory facilities, the purchase
of analytical equipment, and the costs of intellectual property
(patent) protection.
"NanoViricides will benefit from the advanced instrumentation that
TheraCour plans to purchase without having to make the capital
expenditure itself," said Eugene Seymour, MD, MPH, CEO of
NanoViricides, adding, "Availability of larger quantities of our drug
candidates will greatly expedite our drug development for a number of
different viral diseases. This should accelerate our efforts to move
our drugs into the FDA approval process."
About NanoViricides
NanoViricides, Inc. is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's novel
nanoviricide(TM) class of drug candidates are designed to specifically
attack enveloped virus particles and to dismantle them. The Company is
developing drugs against a number of viral diseases including H5N1 bird
flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever,
and Ebola virus, among others.
Feb 09, 2009 -- Unico, Incorporated (OTCBB: UNCO), a natural resource
company in the precious metals mining sector, today announced that
significant levels of tellurium, an extremely rare element, have been
discovered at the company's wholly owned Deer Trail Mine in Marysvale,
Utah. Tellurium, which is used in metal alloys and as a semi-conductor,
has recently experienced increased demand in applications including
optical discs, memory chips and solar panels.
The presence of tellurium at the Deer Trail Mine was discovered during
comprehensive analysis of concentrates at the Deer Trail mill and
processing facility. Unico recently announced the production of
concentrates at the Deer Trail mill, and photo galleries showing
activities at the facility can be viewed at the Unico website.
Metallurgical test work is currently being conducted onsite at the Deer
Trail laboratory. Information on the results completed at the site and
additional analysis conducted by independent 3rd party laboratories are
expected to be announced in the coming days. Test work will also be
conducted on methods for the extraction of tellurium directly from the
concentrates for marketing directly to end users.
There were traditionally very few commercial uses identified for
tellurium, but it has primarily been used as an alloying agent with
copper, steel or lead. It is also used in blasting caps and ceramics.
Recently tellurium has been utilized in ever-increasing applications in
the electronics industry, solar cell electric power generation and as a
semi-conductor.
World tellurium is almost entirely recovered from copper concentrates
during smelting and refining. The supply of this strategic metal was
already in very tight supply prior to the worldwide economic recession,
and the problem has been further exacerbated by the recent reduction in
worldwide copper production. The value of tellurium has recently ranged
in price from $150 to $300 per kilogram, and the current market price
is approximately $180 per kilogram.
"We are pleased with the ongoing work at the Deer Trail Mine, which has
resulted in the discovery of tellurium present in concentrates produced
at the mill site," commented Mark A. Lopez, chief executive officer of
Unico, Inc. "As we continue our activities at the Deer Trail Mine,
which include processing at the mill facility and preparations for
future underground mining activities at the site, we will also explore
all available commercial opportunities for the tellurium discovered
there."
About Unico, Inc.
Unico, Inc. is a publicly traded natural resource company in the
precious metals mining sector that is focused on the exploration,
development and production of gold, silver, lead, zinc, and copper
concentrates at its two mine properties: the Deer Trail Mine and the
Silver Bell Mine. The company has also announced agreements to acquire
over 70 additional mining claims including the Clyde and Crown Point
mining claims. In August 2007, Unico announced that its wholly owned
Deer Trail Mining Company subsidiary had completed the purchase of the
Deer Trail Mine from Crown Mines, LLC.
About PennyPerformers.com
PennyPerformers.com has become one of the premier stops for investors
who wish to experience huge profits via investing in up-and-coming
publicly traded companies.
Penny Performers email report service is free to those investors who
sign up on our website. The alert service is designed to notify
investors of undervalued and often overlooked stocks. Subscribers are
introduced to OTCBB and Pinksheet companies that have the potential of
showing increased activity and Standing Out from the rest of the
market. To subscribe to this free service, visit the Penny Performers
Report home page at www.PennyPerformers.com and select the "join now"
button.
Join us at www.PennyPerformers.com for a complimentary subscription to
the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence.
PennyPerformers.com profiles are not a solicitation or recommendation
to buy, sell or hold securities. PennyPerformers.com is not offering
securities for sale. An offer to buy or sell can be made only with
accompanying disclosure documents and only in the states and provinces
for which they are approved. All statements and expressions are the
sole opinion of the editor and are subject to change without notice.
PennyPerformers.com is not liable for any investment decisions by its
readers or subscribers. It is strongly recommended that any purchase or
sale decision be discussed with a financial adviser, or a
broker-dealer, or a member of any financial regulatory bodies. The
information contained herein has been provided as an information
service only. The accuracy or completeness of the information is not
warranted and is only as reliable as the sources from which it was
obtained. It should be understood there is no guarantee that past
performance will be indicative of future results. Investors are
cautioned that they may lose all or a portion of their investment in
this or any other company. In order to be in full compliance with the
Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and
operated by PennyPerformers.com. Neither PennyPerformers.com nor any of
its affiliates, or employees shall be liable to you or anyone else for
any loss or damages from use of this e-mail, caused in whole or part by
its negligence or contingencies beyond its control in procuring,
compiling, interpreting, reporting, or delivering this Web Site or
e-mail and any contents. Since PennyPerformers.com receives
compensation and its employees or members of their families may hold
stock in the profiled companies, there is an inherent conflict of
interest in PennyPerformers.com statements and opinions and such
statements and opinions cannot be considered independent.
PennyPerformers.com and its management may benefit from any increase in
the share prices of the profiled companies. Information contained
herein contains "forward looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities and Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical facts and may be "forward
looking statements". Forward looking statements are based on
expectations, estimates and projections at the time the statements are
made that involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. PennyPerformers.com services are often paid for using
free-trading shares. PennyPerformers.com may be selling shares of stock
at the same time the profile is being disseminated to potential
investors; this should be viewed as a definite conflict of interest and
as such, the reader should take this into consideration.
Visit us for a full Disclaimer at:
www.PennyPerformers.com/disclaimer.htm
CONTACT: PennyPerformers.com
e-mail: info@pennyperformers.com
WWW: http://www.PennyPerformers.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2009 M2 Communications Ltd.
[ Back To it.tmcnet.com's Homepage ]
|